The impact of chronic renal insufficiency on heart failure mortality after hospitalization

1999 ◽  
Vol 5 (3) ◽  
pp. 70
Author(s):  
Sohail Hassan ◽  
Steven Borzak ◽  
Edward F. Philbin ◽  
Sandeep Soman ◽  
Shalin Shah ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Insufficiency ◽  
Chronic Renal Insufficiency ◽  
The Impact

scholarly journals THE OPTIMIZATION OF DIALYSIS PROGRAM FOR UREMIC POLYNEUROPATHY TREATMENT

2014 ◽  
Vol 5 (1) ◽  
pp. 12-16
Author(s):  
A N Fedoseev ◽  
V V Shestakov ◽  
I N Vaulin ◽  
A S Vaulina ◽  
V V Smirnov ◽  
...  
Keyword(s):  
Renal Insufficiency ◽  
Chronic Renal Insufficiency ◽  
Functional Activity ◽  
Peripheral Nerves ◽  
Motor Deficit ◽  
Neurological Manifestations ◽  
Dialysis Treatment ◽  
Terminal Stage ◽  
Regular Dialysis Treatment ◽  
The Impact

The impact of changes dialysis program on ENMG rates in patients with a terminal stage of chronic renal insufficiency receiving regular dialysis treatment was studied. The study made it possible to determine that the strengthening of the dialysis program with the increase in KT/V to 1.4 promotes regression of neurological manifestations of uremic polyneuropathy and improvement of neurophysiological indicses of functioning of the peripheral nerves in patients with a terminal stage of chronic renal insufficiency. Significantly improved indicators of functional activity as axial cylinders of the peripheral nerves and the myelin sheath. Optimisation of dialysis program allows to improve the functional activity of peripheral nerves already by the end of the first month, the maximum therapeutic effect at 6month treatment and to obtain the steadfast compensation sensory and motor deficit of uremic polyneuropathy. Thus, for the correction of uremic polyneuropathy it is expedient to strengthen the dialysis program with the increase in KT/V to 1.4.

CHLOROTHIAZIDE

PEDIATRICS ◽  
1958 ◽  
Vol 22 (2) ◽  
pp. 236-237
Author(s):  
JOHN D. CRAWFORD
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Carbonic Anhydrase ◽  
Renal Insufficiency ◽  
Chronic Renal Insufficiency ◽  
Free Water ◽  
Carbonic Anhydrase Inhibitor ◽  
Diuretic Agent

CHLOROTHIAZIDE is a new, orally effective diuretic agent chemically related to acetazolamide. Curiously, it is a considerably less potent carbonic anhydrase inhibitor, at least in vitro and, in vivo, its effect has been found additive to that of acetazolamide as it is to the action of the mercurials. Laragh's observations suggest that chlorothiazide inhibits the process of solute reabsorption which normally gives rise to "free" water in the urine. Thus, it may well have a locus of action in the kidney different from that of its chemical cousin or the mercury derivities. There have been optimistic reports of its efficacy in a variety of edema states including nephrosis, cirrhosis of the liver, congestive heart failure, acute hemorrhagic nephritis and chronic renal insufficiency.

Abstract 2222: Long-term Outcomes of Acute Coronary Syndrome Patients with Chronic Renal Insufficiency treated with Bivalirudin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: One Year Results from the Randomized ACUITY Trial

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Roxana Mehran ◽  
Ajay J Kirtane ◽  
George D Dangas ◽  
E. M Ohman ◽  
Stuart Pocock ◽  
...  
Keyword(s):  
High Risk ◽  
Renal Insufficiency ◽  
Major Bleeding ◽  
Chronic Renal Insufficiency ◽  
Coronary Syndrome ◽  
Coronary Syndromes ◽  
Baseline Creatinine ◽  
One Year ◽  
The Impact ◽  
Ischemic Events

Background: In the ACUITY Trial, patients (pts) with chronic renal insufficiency (CRI) had significantly higher rates of ischemic events and major bleeding compared to pts without CRI at 30 days. Bivalirudin (Biv) monotherapy provided similar protection from ischemic events but with significantly less bleeding compared to heparin + a GPIIb/IIIa inhibitor (Hep+GPI). The impact of a Biv alone strategy on one year mortality is unknown. Methods: Pts with moderate and high risk acute coronary syndromes (ACS) were randomized to Hep + GPI, Biv + GPI, or Biv monotherapy. CRI was defined as baseline creatinine clearance (CrCl) <60 mL/min. We evaluated the impact of CRI and antithrombotic strategy on composite ischemia (death, MI, or revascularization) and mortality at one year. Results: Of the pts enrolled, 12,933 had baseline CrCl data: 2468 (19.1%) pts had CrCl ≥60 mL/min and 10,465 (80.9%) pts had CrCl <60 mL/min. Rates of major bleeding at 30 days in pts with CRI were significantly lower with Biv alone vs Hep+GPI (6.2% vs 9.8%, p<0.01). Pts with CRI had higher mortality at one year compared to those without CRI (8.7% vs 3.0%, p<0.001). There was no difference in composite ischemia for pts who received Biv monotherapy vs Hep + GPI (23.0% vs 21.4%, p=0.10). One year mortality by antithrombin strategy is shown in the Figure . Conclusions: CRI in pts with ACS is associated with higher rates of one year mortality. In these high risk pts, Biv monotherapy improved early clinical outcomes compared to Hep + GPI by reducing major bleeding, and resulted in similar rates of one year mortality. Cumulative Mortality at One Year, Patients with CRI

Sign in / Sign up

Export Citation Format

Share Document